Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1085]

Part 4: Clinical decision making - Interpretation of next generation sequencing...

Prof Gunhild von Amsberg and Prof Eva Compérat

Part 4: Clinical decision making - Interpretation of next generation sequencing results ( Prof Gunhild von Amsberg and Prof Eva Compérat )

Part 3: Managing testing efficiencies – How to optimise next generation...

Prof Eva Compérat - Medical University of Vienna, Vienna, Austria

Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing ( Prof Eva Compérat - Medical University of Vienna, Vienna, Austria )

Part 2: How to get biopsies for testing?

Dr Lynda Corrigan and Dr Stephen Finn

Part 2: How to get biopsies for testing? ( Dr Lynda Corrigan and Dr Stephen Finn )

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain

Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )

Machine learning models improve prediction of immunotherapy outcomes across...

Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types ( Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA )

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Prof Rana McKay - University of California San Diego, San Diego, USA

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity ( Prof Rana McKay - University of California San Diego, San Diego, USA )

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise...

Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care ( Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte )

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes...

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in...

Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC ( Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan )

More from ecancer